Perspective Therapeutics Inc Financials

CATX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Neutral

4/9

Perspective Therapeutics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.23x

For every $1 of reported earnings, Perspective Therapeutics Inc generates $0.23 in operating cash flow (-$18.3M OCF vs -$79.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Perspective Therapeutics Inc (CATX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$88.6M

YoY-121.7%

Perspective Therapeutics Inc's EBITDA was -$88.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 121.7% from the prior year.

Free Cash Flow

-$72.7M

YoY-91.4%

Perspective Therapeutics Inc generated -$72.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 91.4% from the prior year.

Net Income

-$79.3M

YoY-70.5%

Perspective Therapeutics Inc reported -$79.3M in net income in fiscal year 2024. This represents a decrease of 70.5% from the prior year.

EPS (Diluted)

$-1.23

YoY+29.3%

Perspective Therapeutics Inc earned $-1.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 29.3% from the prior year.

Cash & Debt

$61.6M

YoY+566.6%

5Y CAGR+63.2%

10Y CAGR+23.1%

Perspective Therapeutics Inc held $61.6M in cash against $1.7M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

71M

YoY+150.8%

5Y CAGR+1.0%

10Y CAGR+2.6%

Perspective Therapeutics Inc had 71M shares outstanding in fiscal year 2024. This represents an increase of 150.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$41.6M

YoY+95.4%

5Y CAGR+95.1%

10Y CAGR+51.2%

Perspective Therapeutics Inc invested $41.6M in research and development in fiscal year 2024. This represents an increase of 95.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$54.4M

YoY+4975.9%

5Y CAGR+161.6%

10Y CAGR+121.6%

Perspective Therapeutics Inc invested $54.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 4975.9% from the prior year.

CATX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$1.4M-76.8%	$6.2M-38.5%	$10.1M+3.9%	$9.7M+32.3%	$7.3M
Cost of Revenue	N/A	N/A	$6.2M+25.3%	$4.9M+8.3%	$4.6M+6.8%	$4.3M
Gross Profit	N/A	$1.4M	$0-100.0%	$5.1M-0.1%	$5.1M+68.2%	$3.0M
R&D Expenses	$41.6M+95.4%	$21.3M+2319.0%	$881K-38.3%	$1.4M+26.7%	$1.1M-23.6%	$1.5M
SG&A Expenses	$26.6M+26.3%	$21.1M+181.4%	$7.5M+59.6%	$4.7M+2.6%	$4.6M+9.6%	$4.2M
Operating Income	-$90.9M-122.0%	-$40.9M-372.1%	-$8.7M-151.7%	-$3.4M+0.9%	-$3.5M+33.8%	-$5.3M
Interest Expense	N/A	$84K	$0	N/A	N/A	N/A
Income Tax	-$2.1M+20.9%	-$2.7M	$0	$0	$0	$0
Net Income	-$79.3M-70.5%	-$46.5M-332.2%	-$10.8M-217.7%	-$3.4M+1.7%	-$3.4M+33.0%	-$5.1M
EPS (Diluted)	$-1.23+29.3%	$-1.74	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Revenue	N/A	N/A	N/A	$2.2M+4.6%	$2.1M+1.2%	$2.1M	N/A	$1.7M
Cost of Revenue	N/A	N/A	N/A	$1.4M-21.4%	$1.8M+16.8%	$1.6M	N/A	$1.3M
Gross Profit	N/A	N/A	N/A	$738K+197.6%	$248K-49.1%	$487K	N/A	$414K
R&D Expenses	$20.3M+69.1%	$12.0M	N/A	$5.6M+3.4%	$5.4M+62.3%	$3.3M	N/A	$708K
SG&A Expenses	$7.7M+10.8%	$7.0M	N/A	$4.5M-10.3%	$5.0M-25.2%	$6.7M	N/A	$3.1M
Operating Income	-$27.9M-49.5%	-$18.6M	N/A	-$9.8M0.0%	-$9.8M+0.1%	-$9.8M	N/A	-$4.2M
Interest Expense	N/A	N/A	N/A	$14K-50.0%	$28K+55.6%	$18K	N/A	$0
Income Tax	N/A	N/A	N/A	$0	$0+100.0%	-$10.5M	N/A	$0
Net Income	-$26.0M-71.7%	-$15.1M	N/A	-$10.4M+6.8%	-$11.1M-2893.5%	-$371K	N/A	-$4.1M
EPS (Diluted)	$-0.35-66.7%	$-0.21	N/A	$-0.37+7.5%	$-0.40	$0.00	N/A	N/A

CATX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$341.1M+248.4%	$97.9M+68.5%	$58.1M-17.5%	$70.4M+709.5%	$8.7M-7.7%	$9.4M
Current Assets	$231.2M+1272.9%	$16.8M-68.4%	$53.2M-20.9%	$67.3M+1122.1%	$5.5M-24.7%	$7.3M
Cash & Equivalents	$61.6M+566.6%	$9.2M-56.0%	$21.0M-67.1%	$63.8M+2568.4%	$2.4M-55.1%	$5.3M
Inventory	N/A	N/A	$1.4M+43.8%	$980K+51.9%	$645K+21.7%	$530K
Accounts Receivable	$116K-90.0%	$1.2M-14.5%	$1.4M-32.3%	$2.0M	N/A	N/A
Goodwill	$0-100.0%	$24.1M	$0	N/A	N/A	N/A
Total Liabilities	$50.4M+122.1%	$22.7M+558.5%	$3.4M+14.6%	$3.0M+1.1%	$3.0M+70.8%	$1.7M
Current Liabilities	$18.2M+16.4%	$15.7M+402.4%	$3.1M+73.1%	$1.8M+14.3%	$1.6M+40.5%	$1.1M
Long-Term Debt	$1.7M-2.8%	$1.7M	N/A	N/A	N/A	N/A
Total Equity	$290.7M+286.6%	$75.2M+37.6%	$54.6M-18.9%	$67.4M+1077.8%	$5.7M-25.5%	$7.7M
Retained Earnings	-$231.7M-52.0%	-$152.4M-43.9%	-$105.9M-16.0%	-$91.3M-3.9%	-$87.9M-4.1%	-$84.5M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Total Assets	$294.8M-13.6%	$341.1M+248.4%	$97.9M-11.4%	$110.5M-8.0%	$120.1M-5.9%	$127.6M+119.7%	$58.1M-7.1%	$62.5M
Current Assets	$178.5M-22.8%	$231.2M+1272.9%	$16.8M-22.4%	$21.7M-32.1%	$32.0M-20.6%	$40.3M-24.3%	$53.2M-7.5%	$57.5M
Cash & Equivalents	$26.8M-56.5%	$61.6M+566.6%	$9.2M-48.6%	$18.0M-36.5%	$28.3M-22.3%	$36.5M+73.6%	$21.0M+10.6%	$19.0M
Inventory	N/A	N/A	N/A	$1.0M-7.4%	$1.1M-22.3%	$1.4M-0.1%	$1.4M-9.3%	$1.6M
Accounts Receivable	$179K+54.3%	$116K-90.0%	$1.2M-32.7%	$1.7M+55.5%	$1.1M-18.4%	$1.4M+0.1%	$1.4M	N/A
Goodwill	N/A	$0-100.0%	$24.1M-11.9%	$27.3M0.0%	$27.3M0.0%	$27.3M	$0	N/A
Total Liabilities	$52.6M+4.3%	$50.4M+122.1%	$22.7M+93.3%	$11.7M+2.2%	$11.5M+19.5%	$9.6M+178.8%	$3.4M-28.7%	$4.8M
Current Liabilities	$20.6M+13.1%	$18.2M+16.4%	$15.7M+93.0%	$8.1M-5.5%	$8.6M+19.4%	$7.2M+130.7%	$3.1M-22.1%	$4.0M
Long-Term Debt	$1.6M-2.3%	$1.7M-2.8%	$1.7M-0.7%	$1.7M-2.0%	$1.8M-1.2%	$1.8M	N/A	N/A
Total Equity	$242.2M-16.7%	$290.7M+286.6%	$75.2M-23.9%	$98.8M-9.1%	$108.7M-7.9%	$118.0M+116.0%	$54.6M-5.3%	$57.7M
Retained Earnings	-$297.4M-28.3%	-$231.7M-52.0%	-$152.4M-19.3%	-$127.8M-8.8%	-$117.4M-10.4%	-$106.3M-0.4%	-$105.9M-3.2%	-$102.7M

CATX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$18.3M+50.4%	-$36.9M-254.9%	-$10.4M-266.6%	-$2.8M+22.1%	-$3.6M+27.9%	-$5.0M
Capital Expenditures	$54.4M+4975.9%	$1.1M+280.1%	$282K-26.0%	$381K+39.6%	$273K-38.5%	$444K
Free Cash Flow	-$72.7M-91.4%	-$38.0M-255.6%	-$10.7M-232.0%	-$3.2M+17.8%	-$3.9M+28.7%	-$5.5M
Investing Cash Flow	-$218.9M-998.3%	$24.4M+184.1%	-$29.0M-6970.2%	-$410K-42.9%	-$287K-171.6%	$401K
Financing Cash Flow	$289.4M+36764.3%	$785K+2703.6%	$28K-100.0%	$64.7M+6407.4%	$994K-86.5%	$7.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Operating Cash Flow	-$16.3M+38.8%	-$26.6M-195.4%	-$9.0M+10.9%	-$10.1M-25.2%	-$8.1M+17.0%	-$9.7M-124.9%	-$4.3M-145.2%	-$1.8M
Capital Expenditures	$2.0M-86.4%	$14.6M+16320.2%	$89K-60.8%	$227K-59.1%	$555K+176.1%	$201K+229.5%	$61K-32.2%	$90K
Free Cash Flow	-$18.3M+55.6%	-$41.2M-353.1%	-$9.1M+12.0%	-$10.3M-19.8%	-$8.6M+13.1%	-$9.9M-126.4%	-$4.4M-136.6%	-$1.9M
Investing Cash Flow	$14.0M+110.1%	-$138.6M-155632.6%	-$89K+60.8%	-$227K+60.4%	-$573K-102.3%	$25.3M+299.3%	$6.3M+118.0%	-$35.2M
Financing Cash Flow	$213K-38.3%	$345K-2.0%	$352K+35100.0%	$1K-99.8%	$512K+740.0%	-$80K	$0-100.0%	$28K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CATX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	100.0%+100.0pp	0.0%-50.9pp	50.9%-2.0pp	52.9%+11.3pp	41.7%
Operating Margin	N/A	-2855.0%-2714.7pp	-140.3%-106.1pp	-34.3%+1.6pp	-35.9%+35.9pp	-71.8%
Net Margin	N/A	-3243.2%-3069.1pp	-174.1%-140.5pp	-33.7%+1.9pp	-35.6%+34.7pp	-70.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-23.2%+24.3pp	-47.5%-29.0pp	-18.5%-13.7pp	-4.8%+34.8pp	-39.6%+15.0pp	-54.6%
Current Ratio	12.68+11.6	1.07-16.0	17.07-20.3	37.37+33.9	3.50-3.0	6.53
Debt-to-Equity	0.01-0.0	0.02-0.0	0.06+0.0	0.04-0.5	0.52+0.3	0.23
FCF Margin	N/A	-2648.9%-2476.0pp	-172.9%-140.9pp	-32.0%+8.4pp	-40.4%+34.7pp	-75.1%

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22
Gross Margin	N/A	N/A	N/A	33.8%+21.9pp	11.9%-11.7pp	23.6%	N/A	24.1%
Operating Margin	N/A	N/A	N/A	-446.2%+20.9pp	-467.1%+6.0pp	-473.1%	N/A	-245.1%
Net Margin	N/A	N/A	N/A	-474.0%+57.9pp	-531.9%-513.9pp	-18.0%	N/A	-236.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-8.8%-4.9pp	-3.9%	N/A	-9.4%-0.1pp	-9.2%-8.9pp	-0.3%	N/A	-6.5%
Current Ratio	8.66-4.0	12.68+11.6	1.07-1.6	2.67-1.0	3.72-1.9	5.60-11.5	17.07+2.7	14.38
Debt-to-Equity	0.010.0	0.01-0.0	0.020.0	0.020.0	0.020.0	0.02-0.0	0.06-0.0	0.08
FCF Margin	N/A	N/A	N/A	-473.1%-59.9pp	-413.2%+67.9pp	-481.1%	N/A	-107.9%

Similar Companies

TriSalus Life Sciences Inc. TLSI

$243.3M

Outset Medical, Inc. OM

$61.6M

Quantum-Si Incorporated QSI

$213.5M

Cerus CERS

$430.3M

Nano-X Imaging Ltd. NNOX

$149.1M

Frequently Asked Questions

Is Perspective Therapeutics Inc profitable?

No, Perspective Therapeutics Inc (CATX) reported a net income of -$79.3M in fiscal year 2024.

What is Perspective Therapeutics Inc's earnings per share (EPS)?

Perspective Therapeutics Inc (CATX) reported diluted earnings per share of $-1.23 for fiscal year 2024. This represents a 29.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Perspective Therapeutics Inc's EBITDA?

Perspective Therapeutics Inc (CATX) had EBITDA of -$88.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Perspective Therapeutics Inc have?

As of fiscal year 2024, Perspective Therapeutics Inc (CATX) had $61.6M in cash and equivalents against $1.7M in long-term debt.

What is Perspective Therapeutics Inc's free cash flow?

Perspective Therapeutics Inc (CATX) generated -$72.7M in free cash flow during fiscal year 2024. This represents a -91.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Perspective Therapeutics Inc's operating cash flow?

Perspective Therapeutics Inc (CATX) generated -$18.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Perspective Therapeutics Inc's total assets?

Perspective Therapeutics Inc (CATX) had $341.1M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Perspective Therapeutics Inc's capital expenditures?

Perspective Therapeutics Inc (CATX) invested $54.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Perspective Therapeutics Inc spend on research and development?

Perspective Therapeutics Inc (CATX) invested $41.6M in research and development during fiscal year 2024.

How many shares does Perspective Therapeutics Inc have outstanding?

Perspective Therapeutics Inc (CATX) had 71M shares outstanding as of fiscal year 2024.

What is Perspective Therapeutics Inc's current ratio?

Perspective Therapeutics Inc (CATX) had a current ratio of 12.68 as of fiscal year 2024, which is generally considered healthy.

What is Perspective Therapeutics Inc's debt-to-equity ratio?

Perspective Therapeutics Inc (CATX) had a debt-to-equity ratio of 0.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Perspective Therapeutics Inc's return on assets (ROA)?

Perspective Therapeutics Inc (CATX) had a return on assets of -23.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Perspective Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Perspective Therapeutics Inc (CATX) had $61.6M in cash against an annual operating cash burn of $18.3M. This gives an estimated cash runway of approximately 40 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Perspective Therapeutics Inc's Piotroski F-Score?

Perspective Therapeutics Inc (CATX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Perspective Therapeutics Inc's earnings high quality?

Perspective Therapeutics Inc (CATX) has an earnings quality ratio of 0.23x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.